| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
|
James, Alexander
|
|
2015
|
76 |
4 |
p. 751-760
|
artikel
|
| 2 |
A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer
|
Fujita, Ken-ichi
|
|
2015
|
76 |
4 |
p. 793-801
|
artikel
|
| 3 |
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
|
Venugopal, B.
|
|
2015
|
76 |
4 |
p. 785-792
|
artikel
|
| 4 |
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
|
Chen, Nianhang
|
|
2015
|
76 |
4 |
p. 699-712
|
artikel
|
| 5 |
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
|
Jones, Robin L.
|
|
2015
|
76 |
4 |
p. 777-784
|
artikel
|
| 6 |
A phase I study of volasertib combined with afatinib, in advanced solid tumors
|
Machiels, Jean-Pascal
|
|
2015
|
76 |
4 |
p. 843-851
|
artikel
|
| 7 |
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review
|
Iuliis, Francesca De
|
|
2015
|
76 |
4 |
p. 679-690
|
artikel
|
| 8 |
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma
|
Tian, Jing
|
|
2015
|
76 |
4 |
p. 829-834
|
artikel
|
| 9 |
Current controversies in the management of metastatic colorectal cancer
|
Vera, Ruth
|
|
2015
|
76 |
4 |
p. 659-677
|
artikel
|
| 10 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
|
Otsuka, Kyoko
|
|
2015
|
76 |
4 |
p. 835-841
|
artikel
|
| 11 |
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
|
Kuwako, Tomohito
|
|
2015
|
76 |
4 |
p. 761-769
|
artikel
|
| 12 |
Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial
|
Simon, Nicolas
|
|
2015
|
76 |
4 |
p. 865-871
|
artikel
|
| 13 |
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
|
Plummer, Ruth
|
|
2015
|
76 |
4 |
p. 723-729
|
artikel
|
| 14 |
Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans
|
Holleran, Julianne L.
|
|
2015
|
76 |
4 |
p. 803-811
|
artikel
|
| 15 |
Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight
|
Bray, Whitney M.
|
|
2015
|
76 |
4 |
p. 691-697
|
artikel
|
| 16 |
Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors
|
Darby, Richard A. J.
|
|
2015
|
76 |
4 |
p. 853-864
|
artikel
|
| 17 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction
|
Motonaga, Masanori
|
|
|
76 |
4 |
p. 713-721
|
artikel
|
| 18 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction
|
Motonaga, Masanori
|
|
2015
|
76 |
4 |
p. 713-721
|
artikel
|
| 19 |
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer
|
Quintero-Aldana, G.
|
|
2015
|
76 |
4 |
p. 731-737
|
artikel
|
| 20 |
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer
|
Mukai, Hirofumi
|
|
2015
|
76 |
4 |
p. 739-750
|
artikel
|
| 21 |
PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3
|
Bol, Guus Martinus
|
|
2015
|
76 |
4 |
p. 821-827
|
artikel
|
| 22 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib
|
Deeken, John F.
|
|
2015
|
76 |
4 |
p. 813-819
|
artikel
|
| 23 |
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents
|
Shukuya, Takehito
|
|
2015
|
76 |
4 |
p. 771-776
|
artikel
|
| 24 |
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study
|
Fang, Luo
|
|
2015
|
76 |
4 |
p. 873-877
|
artikel
|
Tijdschrift beschrijving